



NEWS RELEASE

BIOSYENT NAMED TO THE GROWTH LIST RANKING OF CANADA'S FASTEST-GROWING COMPANIES FOR EIGHTH CONSECUTIVE YEAR

FOR IMMEDIATE RELEASE

OCTOBER 15, 2020

MISSISSAUGA, ONTARIO (October 15, 2020) BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that it has been included in the 32nd annual Growth List, the definitive ranking of Canada's Fastest-Growing Companies by *Canadian Business* and *Maclean's*. The Growth List (formerly the Growth 500) ranks Canadian companies based on five-year revenue growth. Results of the annual ranking are published in a special print issue of *Canadian Business* with *Maclean's* magazine and online at CanadianBusiness.com and GrowthList.ca.

Based on a five-year revenue growth rate of 75% (2014 - 2019), BioSyent was named as one of Canada's Fastest-Growing Companies on the 2020 Growth List. This is the eighth consecutive year that BioSyent has been included in this ranking.

"We are proud to be recognized for our top-line growth among Canada's Fastest-Growing Companies for the eighth consecutive year," commented René Goehrum, President and CEO of BioSyent. "We are also proud of BioSyent's track record of delivering profitability along with this growth, with Q2 2020 marking the 40th consecutive profitable quarter for the Company."

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty/hospital and international business units.

As of the date of this press release, the Company has 12,808,600 shares issued and outstanding.

For further information please contact:

Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.